Take a different approach to hemostasis

Clinical data demonstrate Hemospray’s high success rates

Unlike traditional therapies, Hemospray is a nonthermal, nontraumatic, noncontact modality that doesn’t require the precise targeting of other endoscopic devices. The Hemospray Endoscopic Hemostat creates a mechanical barrier over bleeding sites, and it has demonstrated successful results in a wide range of nonvariceal GI bleeds.

The publication of the largest multicenter international registry of Hemospray patients investigates the efficacy of Hemospray as a monotherapy, as part of a combination therapy, and as a rescue therapy.¹ The registry shows that high hemostasis rates are achieved with Hemospray and that rebleed rates are in keeping with or lower than predicted rates.¹

Learn more about the registry:

The information below was excerpted from a blog post available here: https://www.cookmedical.com/endoscopy/new-registry-demonstrates-hemosprays-high-success-rates/

Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray¹

Prospective data were collected from 314 patients across 12 centers. “These data show high rates of immediate hemostasis overall and in all subgroups.” “Hemospray was effective in achieving primary hemostasis with an overall hemostasis rate of 89.5%.”

Explore our Hemostasis devices

1. Alzoubaidi D, Hussein M, Rusu R, et al. Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray. Dig Endosc. 2020;32(1):96–105.